Tuesday, May 20, 2014

Plandai Biotechnology, Inc. Releases Shareholder Newsletter With Accompanying Video

SEATTLE, WA, United States, via eTeligis Inc., 05/20/2014 - - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today released a shareholder newsletter, which addresses several topics including a "State of the Company" article by the company's Chief Executive Officer that addresses recent milestones and discusses what shareholders can expect in the coming months. Additional articles detail the company's involvement in the cannabis industry -- setting the record straight with respect to current research and future production, the need for the various government agencies to establish "standards" for the cannabis industry, and the company's steps to operate with a zero carbon footprint.

 

Simultaneously, the company released a video that includes never-before-seen footage of the Senteeko tea estate and factory in South Africa, which also provides a graphical presentation on the company's science and competitive advantages. Shareholders and others interested in obtaining the newsletter and previewing the video, but have not previously signed up, can access both at the company's website: www.plandaibiotech.com.

 

Roger Duffield, Chief Executive Officer of Plandaí, commented, "Effective shareholder communications are an important part of our responsibility to everyone that has believed in what we're doing as a company. I've requested that our marketing department commence putting out a quarterly newsletter enabling us to address topics that are of interest to shareholders, but that aren't necessarily suitable for a press release. This edition speaks to the recent fluctuations in stock price while also providing updates on our current operations and strategy through the end of the year. We're also excited to share our new video with people interested in gaining additional insight into Plandaí. We recognize that the science part of what we do is complex and that having our operations overseas makes it challenging for many of our shareholders to both understand what we do and also see the progress. We hope that the newsletter and video, combined with a series of management interviews planned for later this summer, will help everyone feel more connected with Plandaí and help them follow along as we commence full-scale operations."

 

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

 

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

 

Contact:
Andrew Beyer
Phone: 888-627-6902
Email: investor@Plandaíbiotech.com

 

 

SOURCE: Plandai Biotechnology, Inc.

 



Associated Documentation:


Link to submission on http://www.eteligis.com
PLPL_5-20-14_LST_ETL.docx

To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx

Copyright eTeligis Inc. 2014. All rights reserved.

0 comments:

Post a Comment